Home
About
Guruji
Miracles on
Humans
Guruji's
Physiology
Transcendental
Genetics
Transcendental
Science
Microbiology
Agriculture
Publications
Transcendental
Genetics

 
Microbial Genetics
 
 
Staphylococcus aureus strain PS96, ATCC 49831
 
PROJECT REPORT
NAME OF SCIENTIST:
Mr. Mahendra Kumar Trivedi 		SERVICE:
DNA FINGERPRINTING SERVICE (BY RAPD)
SERVICE NO.:
DF 56
 
Project Title DNA Fingerprinting by RAPD Analysis
Cat#: CSER 48
Name of Scientist: Mr. Mahendra Kumar Trivedi
Institute: Life Energies ltd, Mumbai.
Sample name: Staphylococcus aureus strain PS96, ATCC 49831
 
Objective:

The objective of this project is to Genotype five samples (CONTROL Versus TREATED- A, A1, B, B1) of the same line with five primers on Staphylococcus aureus PS96 - ATCC 49831.

Job Requirement:

  • Isolation of genomic DNA from Staphylococcus aureus, PS96 samples.

  • Generating RAPD-Fingerprinting profiles showing Polymorphic bands with five RAPD primers
Gram-positive material and primers

Three series of Inoculums (Control, Series A and Series B) were prepared for Staphylococcus aureus, PS96. The Control series was procured from Bangalore Genei while the Series "A" and series 'B' were handed over to Mr. Mahendra Kumar Trivedi in sealed tubes on 23rd January 2008 during his visit to our R&D facility at Bangalore. On the same day, we provided one isolated room to Mr. Trivedi where he subjected the Series 'A' and Series 'B' to his treatment modality.

Whilst handing over these cultures to Mr. M. K. Trivedi for treatment purposes, optimum precautions were taken to avoid the contamination.

After the presumed treatment, Mr. Trivedi returned the samples to Ms. Bindu Damodaran (Designation - Executive Manager - Microbiology) in the same condition as handed over to him in an hour's time on the same day.

We did not know the treatment modality as it was kept confidential throughout the project.

MATERIALS & METHODS:
  • Sub culturing of treated samples.
1% Inoculum from two treated tubes (series A and series B) was taken and inoculated to fresh 5 ml medium and incubated at 37 C with 160 rpm for 18 hrs and labelled as series A1 and B1 respectively. The cultures were spun down and genomic DNA was isolated.

Genomic DNA was isolated using Ultrapure Genomic DNA prep Kit (Cat# KT 83).

Steps Involved:

  • Genomic DNA was isolated from Staphylococcus aureus samples (Control, Treated A, Treated B provided by Mr. M. K. Trivedi and sub cultured samples Treated A1, Treated B1 provided by Bangalore Genei) using Ultrapure Genomic DNA prep Kit (Cat# KT 83).

  • Performed RAPD reactions using five RAPD primers (RBA Series used separately) to find polymorphism between control and treated samples under PCR conditions as mentioned:

Cycle condition:
94°C
94°C
35°C
72°C
94°C
38°C
72°C
72°C
7 min
60 sec
60 sec
120 sec
60 sec
60 sec
90 sec
7 min
8 cycles
35 cycles
  • 12 of PCR products were loaded on to 1.5 % agarose gel and resolved by electrophoresis. The gel was subsequently stained with ethidium bromide and viewed under UV-light. Photographs were documented subsequently (attached).

  • Polymorphic DNA bands are marked by arrows on the copy of the report.

Fig. 1. RAPD Profile of Staphylococcus aureus samples Generated using Genei
RAPD primer RBA 8A, RBA 13A & RBA 20A.
 
Lane Description:

1: Control
2: Treated A
3: Treated A.1
4: Treated B
5: Treated B.1
M:100 bp Ladder (GeneiTM) Cat # RMBD19S;

Fig. 2. RAPD Profile of Staphylococcus aureus samples Generated using Genei RAPD primer RBA 10A & RBA 15A.
 
 
Lane Description:

1: Control
2: Treated A
3: Treated A.1
4: Treated B
5: Treated B.1
M:100 bp Ladder (GeneiTM) Cat # RMBD19S;
 
Calculation:  
  A/ Bx100 = Percent polymorphism
 
Where,
  
  A= Polymorphic bands in treated plant
B= No of bands in control
 
Sl.
No
Bands scored
Description
Primer
1
14
No band is Common to Control and Treated samples; One band is unique to Control sample; One band is unique to Treated sample A; No band is unique to Treated sample A1; One band is unique to Treated sample B; Three bands are unique to Treated sample B1.
RBA 8A
2
16
One band is Common to Control and Treated samples; Two bands are unique to Control sample; Three bands are unique to Treated sample A; No band is unique to Treated sample A1; Two bands are unique to Treated sample B; No band is unique to Treated sample B1.
RBA 13A
3
13
Three bands are Common to Control and Treated samples; One band is unique to Control sample; Three bands are unique to Treated sample A; No band is unique to Treated sample A1; Two bands are unique to Treated sample B; No band is unique to Treated sample B1.
RBA 20A
4
13
Two bands are Common to Control and Treated samples; One band is unique to Control sample; Three bands are unique to Treated sample A; One band is unique to Treated sample A1; Two bands are unique to Treated sample B; One band is unique to Treated sample B1.
RBA 10A
5
19
One band is Common to Control and Treated samples; One band is unique to Control sample; Three bands are unique to Treated sample A; No band is unique to Treated sample A1; Three bands are unique to Treated sample B; No band is unique to Treated sample B1.
RBA 15A
 
RESULTS & DISCUSSION:

Control & Treated sample A

1. The level of true polymorphism between Control & Treated sample A was evaluated at 87 % with RBA 8A primer.

2. The level of true polymorphism between Control & Treated sample A was evaluated at 71 % with RBA 13A primer.

3. The level of true polymorphism between Control & Treated sample A was evaluated at 87 % with RBA 20A primer.

4. The level of true polymorphism between Control & Treated sample A was evaluated at 69 % with RBA 10A primer.

5. The level of true polymorphism between Control & Treated sample A was evaluated at 81 % with RBA 15A primer.

Control & Treated sample A1

6. The level of true polymorphism between Control & Treated sample A1 was evaluated at 37 % with RBA 8A primer.

7. The level of true polymorphism between Control & Treated sample A1 was evaluated at 57 % with RBA 13A primer.

8. The level of true polymorphism between Control & Treated sample A1 was evaluated at 50 % with RBA 20A primer.

9. The level of true polymorphism between Control & Treated sample A1 was evaluated at 46 % with RBA 10A primer.

10. The level of true polymorphism between Control & Treated sample A1 was evaluated at 36 % with RBA 15A primer.

Control & Treated sample B

11. The level of true polymorphism between Control & Treated sample B was evaluated at 75 % with RBA 8A primer.

12. The level of true polymorphism between Control & Treated sample B was evaluated at 71 % with RBA 13A primer.

13. The level of true polymorphism between Control & Treated sample B was evaluated at 75 % with RBA 20A primer.

14. The level of true polymorphism between Control & Treated sample B was evaluated at 69 % with RBA 10A primer.

15. The level of true polymorphism between Control & Treated sample B was evaluated at 81 % with RBA 15A primer.

Control & Treated sample B1

16. The level of true polymorphism between Control & Treated sample B1 was evaluated at 87 % with RBA 8A primer.

17. The level of true polymorphism between Control & Treated sample B1 was evaluated at 57 % with RBA 13A primer.

18. The level of true polymorphism between Control & Treated sample B1 was evaluated at 37 % with RBA 20A primer.

19. The level of true polymorphism between Control & Treated sample B1 was evaluated at 46 % with RBA 10A primer.

20. The level of true polymorphism between Control & Treated sample B1 was evaluated at 36 % with RBA 15A primer.

Treated sample A & Treated sample A1

21. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 36 % with RBA 8A primer.

22. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 75 % with RBA 13A primer.

23. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 41 % with RBA 20A primer.

24. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 50 % with RBA 10A primer.

25. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 46 % with RBA 15A primer.

Treated sample B & Treated sample B1

26. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 54 % with RBA 8A primer.

27. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 58 % with RBA 13A primer.

28. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 36 % with RBA 20A primer.

29. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 55 % with RBA 10A primer.

30. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 45 % with RBA 15A primer.

Treated sample A & Treated sample B

31. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 12 % with RBA 8A primer.

32. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 0 % with RBA 13A primer.

33. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 12 % with RBA 20A primer.

34. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 0 % with RBA 10A primer.

35. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 0 % with RBA 15A primer.

Treated sample A1 & Treated sample B1


36. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 50 % with RBA 8A primer.

37. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 0 % with RBA 13A primer.

38. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 13 % with RBA 20A primer.

39. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 0 % with RBA 10A primer.

40. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 0 % with RBA 15A primer.

CONCLUSION:

  • Polymorphism was detected between Control & Treated sample A. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 79%.

  • Polymorphism was detected between Control & Treated sample A1. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 45%.

  • Polymorphism was detected between Control & Treated sample B. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 74%.

  • Polymorphism was detected between Control & Treated sample B1. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 52%.

  • Polymorphism was detected between Treated sample A & Treated sample A1. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 49%.

  • Polymorphism was detected between Treated sample B & Treated sample B1. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 49%.

  • Polymorphism was detected between Treated sample A & Treated sample B. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 4.8%.

  • Polymorphism was detected between Treated sample A1 & Treated sample B1. The percentage of true polymorphism observed between Control & Treated samples of Staphylococcus aureus sample is on an average 12.6%.

  • The treatment modality of Mr. Mahendra Kumar Trivedi is not known to us, the company is only concerned about detecting DNA polymorphism in Control & Treated lines of Staphylococcus aureus samples.

Approved by: Dr. Avijit Roy


Manager R & D
Bangalore Genei.


 
Download Original S. AUREUS DNA FINGERPRINTING REPORT - PDF (436 kb)
 
     
     
 
Next page Top
 
     
NEXT REPORT : NOCARDIS OTITIDIS REPORT  
   
RELATED REPORTS :  
   
ANTIBIOTIC SENSITIVITY/BIOCHEMICAL REACTIONS REPORT  
   
MICROBIAL IDENTIFICATION (16S rDNA) REPORT  
   
 
   
     
   
   
Copyright © 2007-2016 Divine Life. All rights reserved | Disclaimer